Study Compared Over 10,000 Cases Across Four Surgical Approaches.

Invivo Robotics (ISIN: CN2347660099), one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery, is pleased to announce that it will publish the results from a new study titled, “Analysis comparing robotic, open, laparoscopic and vaginal hysterectomies performed by high volume surgeons for benign indication.” ..

View more at https://www.1888pressrelease.com/invivo-robotics-study-results-robotic-assisted-benign-hyste-pr-639992.html

The company is also pushing to license its patented products in Japan, Taiwan and Malaysia.

Invivo Robotics (ISIN: CN2347660099), one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery, is pleased to announce new clearances and provided an update on the status of its Invivo Robotics Surgical System (IRSS) staplers.

The Invivo Robotics Surgical System (IRSS) staplers are amongst the few devices ..

View more at https://www.1888pressrelease.com/invivo-robotics-will-bring-stapler-instrumentation-to-invivo-pr-639993.html

Robotic-assisted clinical outcomes again proven to provide economic benefits across healthcare system.

Invivo Robotics (ISIN: CN2347660099), one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery, is pleased to announce the published results of a new study “A Multidimensional Analysis of Prostate Surgery Costs: Robotic-Assisted versus Retropubic Radical Prostatectomy.”

Prostate cancer is the most commonly..

View more at https://www.1888pressrelease.com/invivo-robotics-study-results-cost-savings-associated-with-pr-639994.html

The device is programmed to recognize a target on a cell surface; its drug payload secured within anchor strands of DNA.

Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that scientists, have developed a drug-delivering nanorobot that looks like an open-ended barrel.
The exterior surface of the device is programmed to recognize a target on a cel..

View more at https://www.1888pressrelease.com/nanorobot-as-molecular-scale-a-nano-vivere-study-pr-639968.html

TFhost, the leading Domain Name registrar and Hosting Service Company emerges as the overall best local hosting company in Nigeria for the year 2018.

TFhost, the leading Domain Name registrar and Hosting Service Company emerges as the overall best local hosting company in Nigeria for the year 2018.

This award meant for companies physically hosting websites and domains in Nigeria, was given at a gala dinner hosted by Nigeria Internet Registration Association (NiRA) at Celebration Garden, Ikeja..

View more at https://www.1888pressrelease.com/tfhost-awarded-as-best-local-hosting-company-of-the-year-pr-639961.html

Scientists are currently developing nano-drones that will help prevent heart attacks caused by atherosclerosis.

Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that researchers have developed nanometer-sized drones that deliver drugs to heal and stabilize fat deposits in arteries that could prevent heart attacks caused by atherosclerosi..

View more at https://www.1888pressrelease.com/nano-vivere-this-nano-drone-could-save-you-from-a-heart-att-pr-639970.html

The nanodrug is engineered to cross this barrier with its payload intact, so drugs that are effective outside the brain may be effective inside as well.

Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that its biomedical researchers have invented a tiny drug-delivery system that can identify cancer cell types in the brain through “virtual biopsies” and then attack the molecula..

View more at https://www.1888pressrelease.com/nano-vivere-s-nanotechnology-identifies-brain-tumor-types-th-pr-639969.html

Nano-medicine may be considered to be one of the most significant facets of the still nascent discipline of nanotechnology.

Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that it will discuss in a Nano-conference how nanorobotics (nano-medical devices) may have strong potential for enabling dramatic and beneficial paradigm shifts in virtually ever..

View more at https://www.1888pressrelease.com/nano-medical-robotics-non-invasive-surgery-and-cell-repair-pr-639965.html

The acquisition will add novel scientific platform and manufacturing expertise to Nano Vivere’s research and operational capabilities.

Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that Nano Vivere and global lead in cellular immunotherapy company will sign a definitive merger agreement in which Nano Vivere has agreed to acquire the company. The name of the..

View more at https://www.1888pressrelease.com/nano-vivere-to-acquire-global-leadership-in-cellular-immunot-pr-639963.html

Philip Schwartz is one of if not the highest rated civil lawyers in Palm Beach County. Practicing law in Florida for 25 years. Philip is very aggressive, intelligent and never late. He is a winner. When he is asked by his clients “what he specializes in”? His response is “WINNING”!!!! He strives to achieve the best possible results for each client based upon their specific needs.

Individuals and families generally come to Philip Schwartz at pivotal moments in their lives. They’re often worried, angry, distraught, or grieving. They may be facing divorce, fighting with their child’s other parent, fearful of losing hard-earned assets, or dealing with the illness or incapacity of a loved one. Phil is a master at assuaging anxie..

View more at https://www.1888pressrelease.com/philip-schwartz-law-offices-of-philip-l-schwartz-leads-th-pr-640022.html